|
Denileukin diftitox
resources
|
|
|
|
|
|
DRUG INFO
Denileukin diftitox
Drug Name:
Denileukin diftitox
Indication: For treatment of cutaneous T-cell lymphoma
Pharmacology: Denileukin diftitox (Ontak) directs the cytocidal action of diphtheria toxin to cells which express the IL-2 receptor. The human IL-2 receptor exists in three forms, low (CD25), intermediate (CD122/CD132) and high (CD25/CD122/CD132) affinity. Malignant cells expressing one or more of the subunits of the IL-2 receptor are found in certain leukemias and lymphomas including cutaneous T-cell lymphoma (CTCL). Ontak interacts with the high affinity IL-2 receptor on the cell surface and inhibits cellular protein synthesis, resulting in cell death within hours.
Mechanism Of Action: Ontak binds to the high-affinity IL-2 receptor complex. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes. The diphtheria toxin associated with Ontak then selectively kills the IL-2 bearing cells.
Drug Category: Antineoplastic Agents
Brand Names/Synonyms: Diphtheria toxin precursor;DT;NAD(+--diphthamide ADP- ribosyltransferase); Ontak (Seragen Inc)
Dosage Forms: Not Available
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: Diptheria toxin-Interleukin-2 fusion protein
Chemical Formula: C2560H4042N678O799S17
Half Life: 70-80 min
Drug Type: Approved Drug
# Accession No: BIOD00084
CAS Registry Number: 64365-503-01
|
|
|
|
|
|
Denileukin diftitox News
(When available)
[an error occurred while processing this directive]
Diphtheria Fights Brain Tumors Jan 13, 2006
WNBC, Now, doctors are trying a novel way of killing the cancer, using a kind of chemical Trojan horse to sneak diphtheria toxin into the brain. ...
Biovest International Announces Addition to Senior Management Team Jan 4, 2006
Genetic Engineering News, At Seragen she played a key role in bringing a biologic product (Ontak, for cutaneous T-cell lymphoma) from development through commercialization. ...
|
|
|
